Recombinant human insulin biosimilar - Rechon

Drug Profile

Recombinant human insulin biosimilar - Rechon

Alternative Names: Human insulin - Rechon; Insulin human - Rechon; Insulin human soluble - Rechon; Recombinant human insulin - Rechon

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rechon Life Science
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 1 diabetes mellitus

Most Recent Events

  • 21 Nov 2017 Phase-III clinical trials in Type-1 diabetes mellitus (In the elderly, In adults) in Germany (SC) (EudraCT2016-004691-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top